Main > ONCOLOGY (**) > Skin Cancer>Melanoma>MET>BRAF+*** > Treatment > USA. G. AterolizuMAb+Cobimetinib+

---

USA. G. AterolizuMAb+Cobimetinib+'s subsections
(*) USA Approval Date: 2020. 07.30
+BRAF Gene V600E/K Mutation(+)
+Vemurafenib Inj. IV Use
Company
Patent (A+C)>Assignee; Claims; Etc.
Patent>Total USA No.: 2
Patent>UpDate: 2020. 09.22.
TradeMark

USA. G. AterolizuMAb+Cobimetinib+'s products
This section has no products